31 results about "CKD - chronic kidney disease" patented technology

The invention relates to a balance mechanism and a limb exercise device for rehabilitation of chronic kidney disease. The balance mechanism includes a base, a horizontal plate fixedly installed above and parallel to the base through a vertical plate, and also includes two lower limbs. Stepping assembly, the double lower limbs treading assembly is installed on the base, used for exercising the user's double lower limbs, and the double lower limbs treading assembly is connected to the reciprocating sliding assembly installed on the lower part of the horizontal plate through a transmission assembly , during use, the user exercises both lower limbs through the double lower limb stepping assembly, and the user's double upper limbs are fixed on the two reciprocating plates through the flexible limiting assembly. At this time, the double lower limb stepping assembly is driven by the transmission assembly. The reciprocating sliding component moves, and the reciprocating sliding component drives the two reciprocating plates to drive the user's double upper limbs to swing back and forth, which plays an effective role in balancing exercise for the double upper limbs and the double lower limbs in use.

The invention belongs to the field of Chinese medicines, and relates to a Chinese medicinal compound preparation for preventing and controlling chronic kidney disease and renal fibrosis and a preparation method thereof. On the basis of the theory of 'body resistance weakened while pathogenic factors prevailing, insufficiency of Qi and blood, and blood stasis and collaterals obstruction' in traditional Chinese medical science, the Chinese medicinal compound preparation is prepared from Chinese medicines such as Danshen root, angelica sinensis, peach kernel, twotooth achyranthes root and processed rhubarb. Through animal experiment and clinical trial, the Chinese medicinal compound preparation can improve renal haemodynamics, adjust lipid metabolic disturbance, enhance oxidation resistance, and inhibit over expression of cell factors so as to improve glomerulosclerosis and interstitial fibrosis degree, protect residual renal structures and functions, and delay the process of early-stage and medium-stage chronic renal failure deterioration. The Chinese medicinal compound preparation is particularly suitable for treating patients who suffer from chronic kidney disease (CKD2-4) and renal fibrosis which comprise renal insufficiency, proteinuria, atrophy of kidney and the like.

The invention belongs to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating vascular calcification caused by chronic kidney disease. The traditional Chinese medicine composition is prepared from salted Eucommia ulmoides, Achyranthes bidentata, cooked rhubarb and raw oysters. The weight ratio of each raw material in the traditional Chinese medicine composition is: 1-100 parts of Eucommia ulmoides, 1-100 parts of Achyranthes bidentata, 1-100 parts of cooked rhubarb and 1-100 parts of raw oyster. The traditional Chinese medicine composition of the invention can effectively treat vascular calcification caused by chronic kidney disease.

The invention relates to a novel application of a micro-molecule polypeptide KP-1, and in particular to an application of the micro-molecule polypeptide KP-1 in preparing a medicine for treating chronic kidney diseases (CKD). The invention provides the application of the KP-1 in treating the CKD; and the KP-1 is obvious in curative effect and is free from obvious toxic and side effects. Therefore,the KP-1 provided by the invention can be used for preparing a pharmaceutical preparation for treating the CKD.

The invention discloses an evaluation method for diet protein intake (DPI) of a chronic kidney disease (CKD) patient. Through research of relationships between a fasting serum blood urea nitrogen / creatinine ratio (BUN / Cr) and a single-time urine urea nitrogen / creatinine ratio (UUN / Cr) of a CKD third-phase patient with a stable illness state, and the diet protein intake (DPI), a DPI simple calculation formula based on the fasting serum BUN / Cr and / or random urine UUN / Cr is established. According to the final calculation formula, it is expected that a traditional method for evaluating the DPI through subsistence of the urine within 24 hours can be replaced by a biochemical detection result of a single-time blood or urine in clinical follow-up. Defects such as complexity, long detection time, poor accuracy, difficult sample subsistence or low patient compliance in the traditional method are overcome. Clinically, the method can be used for clinical follow-up, simple blood drawing or single-time urination, thereby evaluating the DPI. The method can be used for managing the diet protein intake of the CKD patient well, fast and conveniently.

The invention belongs to the field of biological medicine, and relates to application of micromolecular polypeptide KP-6, in particular to application of micromolecular polypeptide KP-6 in preparing a drug for treating a chronic kidney disease (CKD). An amino acid sequence of the polypeptide KP-6 is shown as SEQ ID NO. 1. The micromolecular polypeptide KP-6 has a significant effect of inhibiting kidney tissue fibrosis and CKD development, has no obvious toxic or side effects, and therefore can be used for preparing the drug for effectively treating the chronic kidney disease.

The invention belongs to the application field of traditional Chinese medicine in assisting the treatment of improving renal function of patients with chronic kidney disease. Tubulointerstitial fibrosis is a common pathological process that causes CKD to progress to end-stage renal failure caused by various etiologies. Anti-renal fibrosis therapy has become an important link to prevent and delay the progression of CKD. The traditional Chinese medicine composition for assisting in improving renal function of patients with chronic kidney disease of the present invention is composed of the following ingredients in weight ratio: 200-600 parts of astragalus, 200-600 parts of Polygonum multiflorum, 100-300 parts of rhubarb, and 100-300 parts of Ligusticum chuanxiong , 10‑120 parts of leech granules, 200‑600 parts of burnt hawthorn, 200‑800 parts of wax gourd skin, 100‑400 parts of peach kernel, 100‑600 parts of Luo De Da, and 100‑300 parts of Zeilan. In the prescription, Astragalus and Radix Shouwu benefit Qi and kidney as king; leech breaks disease accumulation, removes blood stasis, unblocks blood vessels, and sharpens meridians and tunnels as minister; peach kernel, Chuanxiong, Zelan, hawthorn promote blood circulation and remove blood stasis, rhubarb removes damp turbidity and blood stasis in lower Jiao, Winter melon rind, Zeilan, and Luode are used as adjuvant medicines to relieve water and turbidity. Both experiments and clinics show that the present invention has the effect of auxiliary treatment of renal insufficiency.